- Home
- VRAX vs GTBP Comparison
VRAX vs GTBP Comparison
Compare VRAX & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- GTBP
- Stock Information
- Founded
- VRAX 2013
- GTBP 1965
- Country
- VRAX United Kingdom
- GTBP United States
- Employees
- VRAX N/A
- GTBP N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- VRAX Health Care
- GTBP Health Care
- Exchange
- VRAX Nasdaq
- GTBP Nasdaq
- Market Cap
- VRAX 4.4M
- GTBP 5.5M
- IPO Year
- VRAX 2022
- GTBP N/A
- Fundamental
- Price
- VRAX $0.61
- GTBP $0.79
- Analyst Decision
- VRAX Strong Buy
- GTBP Strong Buy
- Analyst Count
- VRAX 1
- GTBP 1
- Target Price
- VRAX $3.00
- GTBP $11.00
- AVG Volume (30 Days)
- VRAX 1.6M
- GTBP 449.7K
- Earning Date
- VRAX 01-01-0001
- GTBP 11-13-2025
- Dividend Yield
- VRAX N/A
- GTBP N/A
- EPS Growth
- VRAX N/A
- GTBP N/A
- EPS
- VRAX N/A
- GTBP N/A
- Revenue
- VRAX $6,331.00
- GTBP N/A
- Revenue This Year
- VRAX $217,274.83
- GTBP N/A
- Revenue Next Year
- VRAX N/A
- GTBP N/A
- P/E Ratio
- VRAX N/A
- GTBP N/A
- Revenue Growth
- VRAX N/A
- GTBP N/A
- 52 Week Low
- VRAX $0.52
- GTBP $0.63
- 52 Week High
- VRAX $3.62
- GTBP $4.10
- Technical
- Relative Strength Index (RSI)
- VRAX 40.99
- GTBP 29.57
- Support Level
- VRAX $0.54
- GTBP $0.63
- Resistance Level
- VRAX $0.70
- GTBP $0.85
- Average True Range (ATR)
- VRAX 0.06
- GTBP 0.10
- MACD
- VRAX 0.01
- GTBP 0.03
- Stochastic Oscillator
- VRAX 50.56
- GTBP 31.22
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.